Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer
McGahan L
Record ID 32017000423
English
Authors' recommendations:
Overall, olaparib improves PFS and reduces the risk of progression in HER2-negative BRCA-mutated MBC relative to physicians' choice chemotherapy. OlympiAD results hold limited internal and external validity, and follow-up may be insufficient to capture the risk of recurrence or second primary development. While patients are selected based on a confirmed deleterious gBRCAm, there is currently no established biomarker for response to PARPi. Clinical utility of olaparib may be limited as three mechanisms of resistance have already been established. Increasing use of platinum therapy in early TNBC may furthermore influence PARPi use, whilst the optimal PARPi-chemotherapy drug combination remains to be established.
Details
Project Status:
Completed
URL for project:
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published:
2017
URL for published report:
http://eprints.hta.lbg.ac.at/1136/1/DSD_HSO_Nr.71.pdf
URL for additional information:
http://eprints.hta.lbg.ac.at/1136/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Breast Neoplasms
- Humans
- Phthalazines
- Piperazines
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.